MiNK Presentation SITC 2021
Burcu Yigit, Darrian Moskowitz, Xavier Michelet, Antoine Tanne, Marc van Dijk
November 12, 2021
MiNK has initiated studies of agenT-797 for the treatment of patients with relapsed/refractory multiple myeloma and solid tumor cancers.
Early data of single dose administration of AgenT-797 without lymphodepletion in a heavily pre-treated multiple myeloma population refractory to anti-BCMA therapy revealed suppression of M spike protein, tumor cells in the bone marrow, and durable disease stabilization for over 6 months.
MiNK established a xenograft model for the study of agenT-797 to recapitulate human iNKT cell distribution and evaluate efficacy in tumor models. iNKT cells were shown to infiltrate the tumor where they became activated and proliferated over time.
agenT-797 cells are active in vivo in a melanoma solid tumor model A375
iNKTs demonstrated potent tumor killing activity and cytotoxic effects in solid and liquid malignancies. An overall reduction in tumor size was seen with iNKT injection compared to the control group, demonstrating the impact of iNKT cells on tumor growth.
Invariant Natural Killer T (iNKT) cells are key effectors and regulators of immune responses, making them an ideal immunotherapy.
In cancer, iNKT cells reshape the tumor microenvironment:
In viral lung disease, iNKT cells:
MiNK’s iNKT cell manufacturing is scalable